{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:46:36Z","timestamp":1774399596119,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3n Sales"},{"name":"Fundaci\u00f3n Cancer FUCA"},{"name":"Fundaci\u00f3n P. Mosoteguy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00262-019-02391-z","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T06:02:56Z","timestamp":1568268176000},"page":"1585-1596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients"],"prefix":"10.1007","volume":"68","author":[{"given":"Estefan\u00eda Paula","family":"Juli\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Mand\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manglio Miguel","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo Rub\u00e9n","family":"Cueto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florencia","family":"Tsou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina","family":"Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Pupareli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia In\u00e9s","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Astorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Mordoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2954-6667","authenticated-orcid":false,"given":"Estrella Mariel","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,12]]},"reference":[{"key":"2391_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WEE, Poddubskaya E et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123\u2013135","journal-title":"N Engl J Med"},{"key":"2391_CR2","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856\u20131867","journal-title":"N Engl J Med"},{"key":"2391_CR3","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","volume":"17","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF et al (2016) Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17:1558\u20131568","journal-title":"Lancet Oncol"},{"key":"2391_CR4","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803\u20131813","journal-title":"N Engl J Med"},{"key":"2391_CR5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320\u2013330","journal-title":"N Engl J Med"},{"key":"2391_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134\u2013144","journal-title":"N Engl J Med"},{"key":"2391_CR7","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","volume":"31","author":"JS Weber","year":"2013","unstructured":"Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD et al (2013) Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -Naive Melanoma. J Clin Oncol 31:4311\u20134318","journal-title":"J Clin Oncol"},{"key":"2391_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375\u2013384","journal-title":"Lancet Oncol"},{"key":"2391_CR9","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:908\u2013918","journal-title":"Lancet Oncol"},{"key":"2391_CR10","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455\u20132465","journal-title":"N Engl J Med"},{"key":"2391_CR11","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","volume":"33","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR et al (2015) Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 33:1430\u20131437","journal-title":"J Clin Oncol"},{"key":"2391_CR12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","volume":"34","author":"DF McDermott","year":"2016","unstructured":"McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O et al (2016) Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase ia study. J Clin Oncol 34:833\u2013842","journal-title":"J Clin Oncol"},{"key":"2391_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563\u2013567","journal-title":"Nature"},{"key":"2391_CR14","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018\u20132028","journal-title":"N Engl J Med"},{"key":"2391_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","volume":"16","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Mazi\u00e8res J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ et al (2015) Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16:257\u2013265","journal-title":"Lancet Oncol."},{"key":"2391_CR16","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim D-W, Felip E, P\u00e9rez-Gracia JL, Han J-Y et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540\u20131550","journal-title":"Lancet"},{"key":"2391_CR17","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:1837\u20131846","journal-title":"Lancet"},{"key":"2391_CR18","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 17:e542\u2013e551","journal-title":"Lancet Oncol."},{"key":"2391_CR19","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH et al (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20:5064\u20135074","journal-title":"Clin Cancer Res"},{"key":"2391_CR20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275\u2013287","journal-title":"Nat Rev Cancer"},{"key":"2391_CR21","volume-title":"InfoStat versi\u00f3n 2017","author":"JA Di Rienzo","year":"2017","unstructured":"Di Rienzo JA, Casanoves F, Balzarini MG, Gonzalez L, Tablada MRC (2017) InfoStat versi\u00f3n 2017. Grupo InfoStat, FCA, Universidad Nacional de C\u00f3rdoba, Argentina"},{"key":"2391_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-87458-6","volume-title":"Mixed effects models and extensions in ecology with R","author":"AF Zuur","year":"2009","unstructured":"Zuur AF, Ieno EN, Walker N, Saveliev AA, Smith GM (2009) Mixed effects models and extensions in ecology with R. Springer, New York"},{"key":"2391_CR23","doi-asserted-by":"publisher","first-page":"e1005752","DOI":"10.1371\/journal.pcbi.1005752","volume":"13","author":"F Rohart","year":"2017","unstructured":"Rohart F, Gautier B, Singh A, L\u00ea Cao KA (2017) mixOmics: an R package for \u2018omics feature selection and multiple data integration. PLoS Comput Biol 13:e1005752","journal-title":"PLoS Comput Biol"},{"key":"2391_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.chemolab.2018.02.004","volume":"175","author":"V Trivittayasil","year":"2018","unstructured":"Trivittayasil V, Tsuta M, Kasai S, Matsuo Y, Sekiyama Y, Shoji T et al (2018) Classification of 1-methylcyclopropene treated apples by fluorescence fingerprint using partial least squares discriminant analysis with stepwise selectivity ratio variable selection method. Chemom Intell Lab Syst. 175:30\u201336","journal-title":"Chemom Intell Lab Syst."},{"key":"2391_CR25","unstructured":"Wei T, Simko V (2017) R package \u201ccorrplot\u201d: Visualization of a Correlation Matrix (Version 0.84). Available from \n                    https:\/\/github.com\/taiyun\/corrplot\n                    \n                  . Accessed Jan 2019"},{"key":"2391_CR26","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1158\/2326-6066.CIR-15-0043","volume":"3","author":"M Callea","year":"2015","unstructured":"Callea M, Albiges L, Gupta M, Cheng S-C, Genega EM, Fay AP et al (2015) Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma. Cancer Immunol Res 3:1158\u20131164","journal-title":"Cancer Immunol Res"},{"key":"2391_CR27","doi-asserted-by":"publisher","first-page":"166","DOI":"10.7150\/jca.8167","volume":"5","author":"LB Jilaveanu","year":"2014","unstructured":"Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y et al (2014) PD-L1 expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metastases. J Cancer. 5:166\u2013172","journal-title":"J Cancer."},{"key":"2391_CR28","doi-asserted-by":"publisher","first-page":"90123","DOI":"10.18632\/oncotarget.21485","volume":"8","author":"E Munari","year":"2017","unstructured":"Munari E, Zamboni G, Marconi M, Sommaggio M, Brunelli M, Martignoni G et al (2017) PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. Oncotarget. 8:90123\u201390131","journal-title":"Oncotarget."},{"issue":"682\u2013691","key":"2391_CR29","first-page":"e5","volume":"18","author":"D Casadevall","year":"2017","unstructured":"Casadevall D, Clav\u00e9 S, Taus \u00c1, Hardy-Werbin M, Rocha P, Lorenzo M et al (2017) Heterogeneity of tumor and immune cell PD-L1 expression and lymphocyte counts in surgical NSCLC samples. Clin Lung Cancer 18(682\u2013691):e5","journal-title":"Clin Lung Cancer"},{"key":"2391_CR30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nm.4466","volume":"24","author":"C Krieg","year":"2018","unstructured":"Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM et al (2018) High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med 24:144\u2013153","journal-title":"Nat Med"},{"key":"2391_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.01613","volume":"9","author":"N Manjarrez-Ordu\u00f1o","year":"2018","unstructured":"Manjarrez-Ordu\u00f1o N, Menard LC, Kansal S, Fischer P, Kakrecha B, Jiang C et al (2018) Circulating T cell subpopulations correlate with immune responses at the tumor site and clinical response to PD1 inhibition in non-small cell lung cancer. Front Immunol. 9:1\u20139","journal-title":"Front Immunol."},{"key":"2391_CR32","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8:1069\u20131086","journal-title":"Cancer Discov"},{"key":"2391_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ctrv.2016.11.007","volume":"52","author":"JS O\u2019Donnell","year":"2017","unstructured":"O\u2019Donnell JS, Long GV, Scolyer RA, Teng MWL, Smyth MJ (2017) Resistance to PD1\/PDL1 checkpoint inhibition. Cancer Treat Rev 52:71\u201381","journal-title":"Cancer Treat Rev"},{"key":"2391_CR34","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168:707\u2013723","journal-title":"Cell"},{"key":"2391_CR35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2017.11.012","volume":"89","author":"M Ameratunga","year":"2018","unstructured":"Ameratunga M, Ch\u00e9nard-Poirier M, Moreno Candilejo I, Pedregal M, Lui A, Dolling D et al (2018) Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1\/PD-L1 inhibitors. Eur J Cancer 89:56\u201363","journal-title":"Eur J Cancer"},{"key":"2391_CR36","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2147\/OTT.S153290","volume":"11","author":"DB Sacdalan","year":"2018","unstructured":"Sacdalan DB, Lucero JA, Sacdalan D (2018) Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther. 11:955\u2013965","journal-title":"Onco Targets Ther."},{"key":"2391_CR37","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","volume":"22","author":"B Weide","year":"2016","unstructured":"Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K et al (2016) Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res 22:5487\u20135496","journal-title":"Clin Cancer Res"},{"key":"2391_CR38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40425-018-0328-8","volume":"6","author":"PB Subrahmanyam","year":"2018","unstructured":"Subrahmanyam PB, Dong Z, Gusenleitner D, Giobbie-Hurder A, Severgnini M, Zhou J et al (2018) Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. J Immunother Cancer. 6:18","journal-title":"J Immunother Cancer."},{"key":"2391_CR39","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1093\/annonc\/mdx190","volume":"28","author":"MF Sanmamed","year":"2017","unstructured":"Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME et al (2017) Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann Oncol 28:1988\u20131995","journal-title":"Ann Oncol"},{"key":"2391_CR40","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/2326-6066.CIR-15-0097","volume":"3","author":"DS Thommen","year":"2015","unstructured":"Thommen DS, Schreiner J, Muller P, Herzig P, Roller A, Belousov A et al (2015) Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. Cancer Immunol Res 3:1344\u20131355","journal-title":"Cancer Immunol Res"},{"key":"2391_CR41","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG et al (2016) Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 7:10501","journal-title":"Nat Commun."},{"key":"2391_CR42","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK (2016) Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44:989\u20131004","journal-title":"Immunity"},{"key":"2391_CR43","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s00262-018-2225-x","volume":"67","author":"R Kato","year":"2018","unstructured":"Kato R, Yamasaki M, Urakawa S, Nishida K, Makino T, Morimoto-Okazawa A et al (2018) Increased Tim-3\u2009+\u2009T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients. Cancer Immunol Immunother 67:1673\u20131683","journal-title":"Cancer Immunol Immunother"},{"key":"2391_CR44","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207:2187\u20132194","journal-title":"J Exp Med"},{"key":"2391_CR45","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","volume":"71","author":"SF Ngiow","year":"2011","unstructured":"Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MWL, Smyth MJ (2011) Anti-TIM3 antibody promotes T cell IFN-\u2014mediated antitumor immunity and suppresses established tumors. Cancer Res 71:3540\u20133551","journal-title":"Cancer Res"},{"key":"2391_CR46","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","volume":"117","author":"Q Zhou","year":"2011","unstructured":"Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH et al (2011) Coexpression of Tim-3 and PD-1 identifies a CD8\u2009+\u2009T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117:4501\u20134510","journal-title":"Blood"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02391-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-019-02391-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02391-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T23:12:33Z","timestamp":1599779553000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-019-02391-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,12]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["2391"],"URL":"https:\/\/doi.org\/10.1007\/s00262-019-02391-z","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,12]]},"assertion":[{"value":"2 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Claudio Mart\u00edn has served as speaker and advisory board member for Bristol Myers Squibb and Merck Sharp and Dohme. Carmen Pupareli has served as speaker and advisor board member for Merck Sharp and Dohme and as speaker for Bristol Myers Squibb. The authors declare that there is no other conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Comit\u00e9 de \u00c9tica en Investigaci\u00f3n del Instituto Alexander Fleming CEIAF, approval number: 616, 14th June 2016.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and ethical standards"}},{"value":"All samples were taken after patients gave written informed consent approved by Comit\u00e9 de \u00c9tica en Investigaci\u00f3n del Instituto Alexander Fleming CEIAF. Patients consented to the use of their specimens and data for research and for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}